

INVOLVEMENT OF RAS IN CALCIUM SIGNALING INDUCED BY LTD₄ IN U937 LEUKEMIA CELLS

Ravasi S., 2° anno di corso del Dottorato in Scienze Farmacotossicologiche, Farmacognostiche e Biotecnologie Farmaceutiche, XVI ciclo. Durata del Dottorato in anni: 4. Sede di servizio: Dipartimento di Scienze Farmacologiche di Milano Via Balzaretti, 9 - 20133 Milano

It has been shown that DMSO-differentiated promonocytic cell line U937 (dU937) express high affinity binding sites for LTD₄ and that LTD₄ is able to induce [Ca²⁺]_i transient. We confirmed the presence of CysLT₁ receptor by RT-PCR and Western-Blot analysis and we also demonstrated that [Ca²⁺]_i increase induced by 10 nM LTD₄ (fold increase over basal = 3.61 ± 0.19 S.E.M.) was completely inhibited by the Cys-LT₁ receptor antagonists pranlukast (1 μM) and zafirlukast (1 μM). In addition, LTD₄ signal was only partially sensitive to pertussis toxin (-51% at 100 ng/ml, p<0.01), but completely inhibited by U-73122 (500 nM) suggesting the involvement of Gi/o proteins and of phospholipase C respectively. Furthermore, *Cl. sordelli* lethal toxin (100 ng/ml), a specific inhibitor of Ras family GTPases, was able to inhibit LTD₄-induced [Ca²⁺]_i increase (-65%, p<0.01), while *Cl. difficile* toxin B (30 ng/ml), a specific inhibitor of Rho family GTPases, had no effect.

In line with a supposed role of Ras in LTD₄-induced [Ca²⁺]_i elevation, treatment of the cells with FTS (dbch100 μM), a potent prenylated Ras methyltransferase inhibitor, also decreased LTD₄ signal (-32%, p<0.05). Finally, using a Ras pull-down assay, we were able to demonstrate that LTD₄ induces Ras activation (+122%, p<0,05) an effect that is blocked by the two CysLT₁ receptor antagonists pranlukast (1 μM) and zafirlukast (1 μM).